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Abstract
Background: Urogenital schistosomiasis, caused by infection with Schistosoma haematobium, is widespread and causes
substantial morbidity on the African continent. The infection has been suggested as an unrecognized risk factor for incident
HIV infection. Current guidelines recommend preventive chemotherapy, using praziquantel as a public health tool, to avert
morbidity due to schistosomiasis. In individuals of reproductive age, urogenital schistosomiasis remains highly prevalent
and, likely, underdiagnosed. This comprehensive literature review was undertaken to examine the evidence for a cause-
effect relationship between urogenital schistosomiasis and HIV/AIDS. The review aims to support discussions of urogenital
schistosomiasis as a neglected yet urgent public health challenge.
Methodology/Principal Findings: We conducted a systematic search of the literature including online databases, clinical
guidelines, and current medical textbooks. We describe plausible local and systemic mechanisms by which Schistosoma
haematobium infection could increase the risk of HIV acquisition in both women and men. We also detail the effects of S.
haematobium infection on the progression and transmissibility of HIV in co-infected individuals. We briefly summarize
available evidence on the immunomodulatory effects of chronic schistosomiasis and the implications this might have for
populations at high risk of both schistosomiasis and HIV.
Conclusions/Significance: Studies support the hypothesis that urogenital schistosomiasis in women and men constitutes a
significant risk factor for HIV acquisition due both to local genital tract and global immunological effects. In those who
become HIV-infected, schistosomal co-infection may accelerate HIV disease progression and facilitate viral transmission to
sexual partners. Establishing effective prevention strategies using praziquantel, including better definition of treatment age,
duration, and frequency of treatment for urogenital schistosomiasis, is an important public health priority. Our findings call
attention to this pressing yet neglected public health issue and the potential added benefit of scaling up coverage of
schistosomal treatment for populations in whom HIV infection is prevalent.
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Introduction
An estimated 207 million people worldwide are infected with
schistosomes [1], and 85% of these cases occur in Africa [1–3].
Schistosomiasis is a disease of poverty that arises in areas with poor
sanitation where people come into contact with urine- or feces-
contaminated water as part of their daily lives [4]. Individuals
living in endemic countries are most commonly infected during
childhood, and the prevalence peaks between the ages of 10 and
20 years [5,6]. For those who are continually reinfected by
contaminated water, schistosomiasis causes a chronic disease over
decades. While the mortality caused by schistosomiasis is low, the
morbidity is high, and includes anemia, stunted growth, and
decreased ability to learn in children [1]. For these reasons, the
World Health Organization (WHO) recommends annual treat-
ment for school-aged children in areas of high endemicity [7].
Schistosoma haematobium causes more than half (at least 112
million) of worldwide schistosome infections [8]. Formerly known
as urinary schistosomiasis, S. haematobium infection was recently
renamed ‘‘urogenital schistosomiasis’’ in recognition that the
disease affects both the urinary and genital tracts in up to 75% of
infected individuals [9]. Adult S. haematobium worms inhabit the
venules surrounding organs of the pelvis where they lay between
20 and 200 eggs daily [4]. These eggs subsequently penetrate the
vessel wall and move towards the lumen of the bladder. An
important proportion of the eggs become sequestered in the tissue
of pelvic organs such as the urinary bladder, lower ureters, cervix,
vagina, prostate gland, and seminal vesicles, where they cause
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of symptoms and signs including pelvic pain, postcoital bleeding, and
an altered cervical epithelium in women [10–11], and ejaculatory
pain, hematospermia and leukocytospermia in men [12–13].
Epidemiologic mapping studies of HIV and S. haematobium in
Africa depict a substantial overlap, in many regions, between areas
in which S. haematobium is endemic and areas in which women have
a high prevalence of HIV infection (Figure 1) [14]. In particular,
HIV studies report an unexplained gender quotient disfavoring
women over men [15–16]. In rural women whose limited access to
clean water more often puts them at risk for schistosomiasis, HIV
prevalence also peaks at younger ages than in urban women [17].
While some of this skewing has been attributed to social,
behavioral, and cultural norms [17–20], this unexplained gender
quotient also suggests that risk factors for HIV acquisition may be
different between rural and urban populations [17].
Several cross-sectional studies have reported associations
between urogenital schistosomiasis and HIV, but the infection
still receives relatively little attention. Global Burden of Disease
(e.g. disability-adjusted life years [DALY]) calculations treat
schistosomiasis cases as a single sequel, leading others to argue
that the estimates should be much higher [21–23]. Furthermore,
DALY calculations have neither examined urogenital schistoso-
miasis as an entity separate from intestinal schistosomiasis nor
considered it as a population-attributable risk factor for HIV
transmission. Thus urogenital schistosomiasis remains a neglected
disease, particularly in women and men of reproductive age.
This comprehensive literature review was undertaken to examine
the evidence for a cause-effect relationship between urogenital
schistosomiasis and HIV/AIDS. Our aim is to supportdiscussionsof
urogenital schistosomiasis as an urgent public health challenge [24].
Methods
We conducted a broad review of the literature by performing a
systematic search of online databases including PUBMED/
MEDINE, EMBASE, POPLINE, GLOBAL HEALTH, and
Figure 1. Geographical overlap of S. haematobium and HIV infections [14-15].
doi:10.1371/journal.pntd.0001396.g001
Author Summary
Urogenital schistosomiasis is a parasitic infection caused by a
worm, Schistosoma haematobium, which lives in the
bloodstream of infected individuals. It affects at least 112
million people, mostly in sub-Saharan Africa, and has been
suggested to be a risk factor for becoming infected with HIV.
We reviewed publications in order to examine whether it
seems likely that this parasitic infection could be a risk factor
for HIV. Evidence from many types of studies supports the
hypothesis that urogenital schistosomiasis does increase a
person’s risk of becoming infected with HIV. Studies also
suggest that individuals who have both urogenital schisto-
somiasis and HIV have a more aggressive HIV infection and
can more easily transmit HIV to their sexual partners.
Praziquantel is an oral, nontoxic, inexpensive medication
that is safe in pregnancy and is recommended for treatment
of schistosomiasis. In areas where both infections co-exist,
regular administration of praziquantel both to young girls
and to sexually-active women may be an important
approach to reducing HIV transmission. Our findings support
the importance of making praziquantel more available to
people who live in areas of the world where both urogenital
schistosomiasis and HIV infection are widespread.
Urogenital Schistosomiasis and HIV
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the text string ‘schistosom’ in all possible combinations with ‘HIV’,
‘HIV/AIDS’, and other related keywords including ‘urinary,’
‘genital’, ‘gynecology’, and ‘adolescent.’ Case reports were
excluded. We subsequently limited our search to articles published
in the past 30 years which overlap with the HIV pandemic.
We also reviewed the most current editions of widely-used
infectious diseases textbooks [6,25–28] and WHO websites for
relevant publications. We screened titles and abstracts for
relevance, and subsequently reviewed the full texts of manuscripts
that were potentially pertinent. Notable manuscripts and key
learning points that emerged during our review are summarized in
Tables 1 and 2.
Results and Discussion
Local Effects of Urogenital Schistosomiasis and
Susceptibility to HIV Infection in Women
Macroscopic Tissue Damage. Reported symptoms of
female genital schistosomiasis include infertility, pelvic discomfort,
dyspareunia, contact and spontaneous bleeding, itching, and giant
granulomata that appear as tumors [10–11,29–30]. The condition
has been associated with mucosal edema, erosion and ulcerations
leading to a friable epithelium [10], most commonly on the cervix
[29]. Similar breaches in the integrity of the genital epithelium,
whether due to trauma or to sexually-transmitted ulcerative dis-
eases, have been associated with an increased risk of HIV infection.
The epithelial damage caused by S. haematobium infection, which has
been observed to persist even after treatment, has been suggested to
ease viral entry and therefore could serve as a facilitating factor for
acquisition of HIV [11,31–32]. Schistosomiasis in the female genital
tract has been postulated to pose a greater risk than bacterial genital
ulcer disease because, unlike many common sexually-transmitted
infections (STIs), it often is not restricted to a single localized sore
that allows the rest of the vulval, vaginal or cervical epithelium to
remain intact [33].
As they can become sequestered in any genital organ, schis-
tosomal ova cause a spectrum of clinical pathology. ‘‘Grainy sandy
patches,’’ which are tiny cervical abnormalities similar to sandy
patches in the bladder, have been recognized as pathognomonic for
female genital schistosomiasis [10]. Grainy sandy patches have been
described as rough small grains located superficially within the
mucosa [10]. A second type of sandy patch, the ‘‘homogeneous
yellow sandy patch,’’ has also been associated with S. haematobium
infection but is less specific since it is also associated with STIs [10].
Grainy sandy patches are often encircled by irregularly-formed
blood vessels believed to represent egg-induced neovascularization
[10,34]. This may explain the contact bleeding that is associated
with genital tract S. haematobium infection and could be one
mechanism by which HIV risk is enhanced.
Microscopic Tissue Damage. Sequestered schistosomal ova
have been shown to evoke a complex cellular and humoral
immune response in tissue. The ova of S. haematobium can induce
areas of inflammation or of large granulomata in the female
genital tract, with recruitment of plasma cells, lymphocytes,
granulocytes, macrophages, and eosinophils to the site [35–36].
These inflammatory cells express CD4+ T-cell receptors, which
are the primary targets for HIV. This activity at cellular level in
genital lesions caused by schistosomiasis is potentially comparable
to lesions caused by primary and secondary syphilis and herpes
simplex virus infections (HSV-1 and HSV-2), in which affected
tissue was shown to have more HIV receptors than healthy tissue
Table 1. Five key papers in the field.
1 Kjetland EF, Ndhlovu PD, Gomo E, Mduluza T, Midzi N, et al (2006) Association between genital schistosomiasis and HIV in rural Zimbabwean women.
AIDS 20(4): 593–600.
2 Leutscher PDC, Pedersen M, Raharisolo C, Jensen JS, Hoffmann S, et al (2005) Increased prevalence of leukocytes and elevated cytokine levels in semen
from Schistosoma haematobium-infected individuals. J Infect Dis 191: 1639–47.
3 Secor WE (2006) Interactions between schistosomiasis and HIV-1. Parasit Immunol 28: 597–603.
4 Kallestrup P, Zinyama R, Gomo E, Butterworth AE, Mudenge B, et al (2005) Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of
schistosomiasis on CD4 count and plasma HIV-1 RNA load. J Infect Dis 192(11): 1956–61.
5 Poggensee G and Feldmeier H (2001) Female genital schistosomiasis: facts and hypotheses. Acta Tropica 79: 193–210.
doi:10.1371/journal.pntd.0001396.t001
Table 2. Key learning points.
1 Schistosoma haematobium infection has been recently renamed ‘‘urogenital schistosomiasis’’ by the World Health Organization because of its tissue-
damaging effects of both the urinary and genital tracts.
2 S. haematobium ova in the female genital tract (typically the cervix and vagina) cause epithelial inflammation leading to erosions and ulcerations. These
epithelial breaches may facilitate HIV viral entry and binding to immune cells present in the altered epithelium.
3 In men with S. haematobium infection, genital organs and semen show inflammatory alterations that may imply an increased risk of HIV transmission from
men to women.
4 Chronic schistosomiasis promotes a Th2-type immune environment in the host that may increase susceptibility to HIV infection and viral propagation.
5 In HIV-positive individuals, co-infection with schistosomes appears to raise HIV RNA levels and decrease CD4+ T-cell counts more rapidly than in those
without co-infection. This could lead to a more rapid disease progression and a higher viral load which, in turn, enhances virus shedding through genital
secretions.
doi:10.1371/journal.pntd.0001396.t002
Urogenital Schistosomiasis and HIV
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with S. mansoni have been reported to display higher surface
densities of Schistosoma-induced chemokine receptors CCR5 and
CXCR4 [38].
Inflammation provoked by ova in genital tissue has thus been
postulated to recruit these activated immune cells expressing CD4,
CXCR4, and CCR5 receptors into the epithelium, facilitating
rapid binding of the virus after penetration through an ulcerated,
friable epithelium [39]. In support of this hypothesis, rhesus
macaques with acute S. mansoni infection were found to be more
susceptible to development of systemic HIV infection after rectal
HIV exposure than were macaques without S. mansoni [40].
Because macaques did not have statistically-significant differences
in the rates of HIV infection after intravenous HIV exposure, the
authors concluded that the increased host susceptibility to HIV in
the setting of schistosomal infection that they observed was
predominantly due to mucosal inflammation [40].
Findings from Clinico-Epidemiological Studies. Af e w
cross-sectional studies in women support an association between
urogenital schistosomiasis and HIV infection (Table 3). In
Zimbabwe, women with urinary schistosomiasis had a higher HIV
prevalence (33.3%) than women without urinary schistosomiasis
(HIV prevalence of 25.6%, p=0.053) [41]. Women with S. hae-
matobiumovainthegenitaltracthadnearlyathree-foldincreasedrisk
of having HIV [34]. In Tanzania, women with S. haematobium
infection had a four-fold increased risk of HIV [42].
Taken together, these studies included more than 1000 African
women from rural communities with the consistent finding that S.
haematobium infection was associated with HIV, with odds ratios
between 2.9 and 4.0. Each of these studies is limited by its cross-
sectional nature, which allows determination only of an association,
rather than of a cause-effect relationship, between S. haematobium
infection and HIV. Because S. haematobium infection, typically
acquired in childhood, normally precedes HIV acquisition, it seems
likely that S. haematobium infection may increase the susceptibility to
HIV infection when girls reach sexual maturity. Definitive proof of
this hypothesis can only be ascertained through longitudinal studies
thatarecarefullyplannedtodemonstrateacause-effectrelationship.
The design of prospective studies to establish a causal rela-
tionship would be complex and needs to address difficult ethical
issues concerning gynecological examination of pre-teenage and
teenage girls. Moreover, withholding praziquantel from young
women with documented S. haematobium infection and following
them prospectively as a control group in a study for incident HIV
infections is not ethical. For these reasons, recent study designs
have focused on comparing different mass treatment strategies
among cohorts of girls at different ages in S. haematobium-endemic
communities. For example, young adolescent schoolgirls would
Table 3. Primary studies in individuals with schistosomiasis and HIV infection.
ARTICLE MAJOR FINDING LIMITATIONS
Epidemiological Studies
Ndhlovu P et al, Trans Roy
Soc Trop Med Hyg 2007 [41]
Women in Zimbabwe with urinary schistosomiasis had a higher
prevalence of HIV than those without urinary schistosomiasis
(33% vs. 26%, p=0.053).
Cross-sectional studies and therefore
unable to demonstrate causality.
Kjetland EF et al, AIDS
2006 [32]
HIV was associated with female genital schistosomiasis in
Zimbabwean women (OR=2.9, 95% CI [1.1–7.5]).
Downs JA et al, Am J Trop
Med Hyg 2011 [42]
HIV was associated with S. haematobium infection in Tanzanian
women (OR=4.0 [1.2–13.5]).
Immunological Studies in Individuals with HIV/S. mansoni Co-Infection
Mwinzi PN et al, J Infect Dis
2001 [56]
S. mansoni-infected individuals who were also HIV-positive had
lower levels of Th2-type cytokines than those without HIV,
implying HIV-mediated Th2-type CD4+ T-cell descruction.
Unable to demonstrate definitively that lower
cytokine levels reflect Th2-type cell destruction
by HIV rather than being caused by another mechanism.
Secor WE et al, Infect
Immunol 2003 [38]
Densities of the chemokine receptors CCR5 and CXCR4 on CD4+
T-cells in HIV-positive (and also HIV-negative) individuals with S.
mansoni co-infection were reduced following praziquantel treatment.
Very small observational study; possibility
of selection bias not addressed.
Observational Studies Assessing Effect of Praziquantel Treatment for S. mansoni on HIV-RNA levels in Individuals with HIV Infection
Lawn SD et al, AIDS
2000 [62]
HIV RNA levels increased significantly over a mean of 5.6 months
of follow-up.
Observational studies: -Effects may be more
attributable to length of follow-up time and to
effects of HIV infection than to praziquantel treatment.
-No control groups or randomization.
Elliott AM et al, Trans Roy
Soc Trop Med Hyg 2003 [63]
HIV RNA levels transiently increased (at 5 weeks after treatment)
and then returned to pre-treatment baseline by 4 months.
Brown M et al, J Infect Dis
2004 [64]
HIV RNA levels were not significantly different pre- and
post- treatment in HIV/S. mansoni co-infected individuals.
Modjarrad K et al, J Infect
Dis 2005 [65]
HIV RNA levels increased (nonsignificantly) over the 16-week
post-treatment follow-up.
Brown M et al, J Infect
Dis 2005 [66]
HIV RNA levels transiently increased 1 month after treatment
and then returned to pre-treatment levels by month 5.
Randomized Trial Assessing Effect of Praziquantel Treatment for S. mansoni in Individuals with HIV Infection
Kallestrup P et al, J Infect
Dis 2005 [60]
HIV-positive patients who were randomized to receive
praziquantel immediately had smaller HIV RNA level increases
and increased CD4+ T-cell count compared with those
randomized to treatment after 3 months.
Randomized but not blinded so potential
for bias in follow-up.
doi:10.1371/journal.pntd.0001396.t003
Urogenital Schistosomiasis and HIV
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at the time they commence sexual activity, to older adolescent girls
who received fewer treatments before becoming sexually-active
and to older adolescent ‘‘control’’ girls from the same villages who
are sexually active and did not receive prophylaxis. The hypothesis
is that early, frequent praziquantel treatment will prevent deve-
lopment of genital lesions in adolescence and will consequently
reduce HIV infections in girls and women after sexual debut
[14,43]. Another possibility would be to use recently-developed
serum schistosomal antigen tests, such as the Circulating Anodic
Antigen (CAA) [44,45], to analyze banked serum from prior HIV
seroincidence studies. These study designs also highlight additional
research needs in the field, such as optimization of the prazi-
quantel regimen for treatment of urogenital schistosomiasis and
the need for a standardized, agreed-upon case definition for clini-
cal diagnosis and measurement of morbidity caused by urogenital
schistosomiasis.
Female Genital Schistosomiasis and Shedding of HIV
Concurrent S. haematobium infection may also increase the ease
with which HIV-positive women transmit HIV infection to their
sexual partners. A recent meta-analysis found that a variety of
genital tract infections were associated with HIV-1 viral shedding
in the female genital tract [46]. This effect was most pronounced
in conditions that resulted in the recruitment of high concentra-
tions of leukocytes to the genital epithelium, including nonspecific
cervicitis, genital ulcer diseases, Chlamydia trachomatis and Neisseria
gonorrhea infections, and vulvovaginal candidiasis. The authors
hypothesized that, because leukocytes typically harbor HIV,
conditions that lead to higher genital tract leukocyte concentra-
tions are those that most heighten the risk of sexual HIV
transmission from women to men during sexual intercourse. Given
the recruitment of leukocytes to the genital tract by S. haematobium
infection [35,36], it seems possible that, through this mechanism,
women who are co-infected with HIV and S. haematobium may
more easily transmit HIV to their sexual partners.
Male Urogenital Schistosomiasis and HIV Infection
Genital schistosomiasis in men can involve several male
reproductive organs. Since the penis is not affected by ova-
induced lesions, male genital schistosomiasis is not believed to
increase the risk of HIV acquisition through local effects [43] but
rather through schistosomiasis-related immunomodulatory effects.
Moreover, the infection could increase risk for HIV transmission
by inciting inflammation in the male genital tract. Men with severe
urogenital schistosomiasis have been found to have a higher
prevalence of lymphocytes and eosinophils in seminal fluid than
those without infection [47]. Infected men are also reported to
have significantly higher levels of interleukin (IL)-4, IL-6, IL-10,
and tumor necrosis factor-alpha in their semen. These cytokines
may recruit more HIV-infected cells to the semen, upregulate viral
replication, and increase the concentration of HIV virus in semen
[47]. Six months after anti-schistosomal treatment, the concen-
trations of seminal lymphocytes and eosinophils were lower and
the levels of cytokines were reduced. Another analysis of seminal
fluid in S. haematobium-infected men demonstrated lower volumes
of semen, higher levels of eosinophilic cationic protein (an es-
tablished marker of inflammation and morbidity in urogenital
schistosomiasis), and higher rates of sperm apoptosis, which
lessened after praziquantel treatment [48].
With a mechanism similar to that discussed for women in the
preceding section, it has been demonstrated that HIV-positive
men with concomitant genital tract infections, such as urethritis,
have higher concentrations of seminal HIV-1 RNA than those
without dual infections [49]. The chronic inflammation and
recruitment of lymphocytes and eosinophils to the male genital
tract may increase the HIV-1 viral load in semen. In this manner,
a female sexual partner of an HIV-positive male living in an S.
haematobium-endemic area may have a doubly-amplified risk of
HIV acquisition: her S. haematobium-infected partner’s semen may
contain disproportionately high concentrations of HIV RNA, and
her own S. haematobium infection may increase the ease with which
HIV can establish infection following exposure. Taken together,
these data suggest that egg-induced inflammation in the male
genital tract could be a risk factor for HIV transmission from men
to women.
Schistosomiasis in Children and Adolescents and HIV
Transmission
Schistosomal lesions are commoner in the vulva and the lower
vagina before puberty, while in adult women they are more
frequent in the cervix, uterus, ovaries and fallopian tubes [50].
These clinically-apparent lesions and the resulting compromise of
the vaginal epithelium, therefore, are already present before a
girl’s first sexual intercourse. This is in contrast to lesions caused by
STIs, which can develop only after sexual intercourse [32]. The
presence of schistosomal lesions already in childhood makes it
likely that schistosomal infection typically precedes HIV infection
and that the temporal association reflects the fact that urogenital
schistosomiasis is a risk factor for HIV acquisition rather than vice-
versa [10].
Important risk factors for urinary tract morbidity in adulthood
are cumulative intensity and duration of S. haematobium infection
during early adolescence. Treatment of school-aged children can
significantly reduce the cumulative lifetime egg burden as the
intensity of infection is greatest during early teenage years [50].
Furthermore, treatment for schistosomiasis during childhood was
significantly associated with the absence of cervical sandy patches
and contact bleeding in adult women [51]. Thus treatment of S.
haematobium infection before and during the teenage years may not
only diminish genital schistosomiasis-associated morbidity in
adulthood, but may simultaneously decrease the risk of HIV
acquisition.
Schistosomiasis-Associated Immunomodulation and the
Risk of HIV Infection
In addition to local and gender-specific effects of S. haematobium
infection, schistosomiasis also appears to increase HIV suscepti-
bility through chronic immune modulation. This topic has been
studied far more extensively with regard to Schistosoma mansoni [52].
It has also recently been the subject of a comprehensive review
[31] and for this reason will be summarized only briefly here.
Chronic schistosomiasis alters global immune function and in
this manner may also increase susceptibility to HIV infection [38].
It preferentially stimulates the Th2-type immune response, with
reciprocal down-regulation of the Th1-type cytotoxic responses
[53] which are important in initial control of HIV infection. This is
supported by work from Uganda, which demonstrated that HIV-
positive patients with S. mansoni infection had decreased Gag-
specific cytolytic CD8+ responses [54]. Moreover, CD4+ T-cells
with a Th2 phenotype are more readily infected, and subsequently
destroyed, by HIV-1 than are Th1 cells [55]. In individuals in
Kenya with HIV and S. mansoni co-infection, Th2-type CD4+ T-
cells were destroyed more quickly than in HIV-positive individuals
without schistosomiasis [56].
Specifically, differences in cell surface receptors may lead to
differences in HIV susceptibility between those with and without
Urogenital Schistosomiasis and HIV
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co-receptors for HIV-1 and were found to be more dense on the
CD4+ T-cell surfaces of individuals with active S. mansoni infection
than on the CD4+ T-cells of individuals who had received
prior anti-schistosomal treatment [38]. The levels of these co-
receptors dropped in individuals who were studied pre- and post-
praziquantel treatment [38]. This highlights the potential role that
widespread anti-schistosomal treatment could play in reducing the
progression and spread of HIV.
Effects of Schistosomiasis on Progression of HIV Infection
and Shedding of HIV
In addition to potentially increasing susceptibility to HIV
infection, evidence suggests that S. haematobium infection may also
speed progression of disease by raising plasma HIV RNA
concentration (commonly known as ‘‘viral load’’) in individuals
who are co-infected. At the cellular level, the same CCR5 and
CXCR4 chemokine receptorsthat areupregulated in schistosomiasis
and facilitate HIV binding in initial infection may also promote cell-
to-cell spread of HIV once infection is established [31,57]. Multiple
studies have shown that the plasma HIV RNA level is predictive of
both HIV disease progression and risk of transmission of HIV to
sexual partners [58,59]. If the hypothesis is correct that schistoso-
miasis increases the HIV RNA levels in co-infected individuals, then
treatment for schistosomiasis could delay the development of AIDS
and decrease the spread of HIV in sub-Saharan Africa.
A recent randomized clinical trial conducted in Zimbabwe
supports this hypothesis. Patients who were infected with both HIV
and S. mansoni were randomized either to praziquantel treatment at
enrollment or to praziquantel after three months [60]. Compared
with the group in whom treatment was delayed, the early-treatment
group experienced significantly smaller declines in CD4+ T-cell
counts after three months (mean decline of 1.7 cells/ mL versus
35.2 cells/ mL in the delayed-treatment group) [61]. Notably, the
HIV RNA levels in both groups of patients increased during the
three months, but the mean increase in the early-treatment group
(0.001log10 copies/mL) was significantly lower than in the delayed-
treatment group (0.21log10 copies/mL).
Earlier non-randomized studies of HIV-positive patients who
were treated for S. mansoni infections had found that HIV RNA
levels remained stable or increased in patients regardless of
treatment [62–65]. One notable study that reported significant
HIV RNA level increases one month post-treatment noted
corresponding increases in S. mansoni-specific Th2-type cytokine
responses as well, though both of these reverted to pre-treatment
levels by five months post-treatment [66]. Notably, none of the
patients in these studies were receiving ART. In light of the
findings of the randomized trial in Zimbabwe that did demon-
strate a benefit with praziquantel treatment with regard to the viral
load [60], it is plausible that the overall observed increases in HIV
RNA levels reflect natural progression of untreated HIV infection.
In this sense, while treatment for schistosomiasis is clearly not able
to substitute for antiretroviral therapy, it may possibly be able to
slow HIV disease progression [31].
In support of this hypothesis, two other randomized studies of
HIV-infected patients co-infected with either Wucheria bancrofti [67]
or soil-transmitted helminths [68] have explored the effects of
treatment on parameters of HIV infection. Patients treated for
lymphaticfilariasishadsignificant decreasesintheirHIV RNAlevels
andinsignificantincreasesintheirCD4+T-cellcountsat12weeksas
compared to pretreatment levels [67]. Patients with ascariasis who
received albendazole experienced significantly higher CD4+ T-cell
counts at 12 weeks and a trend towards lower HIV RNA levels [68].
Taken together, these studies of treatment in HIV and helminth
co-infections support a positive effect of antiparasitic treatment on
certain HIV infection parameters. While treatment for schistoso-
miasis in HIV-positive patients may not decrease HIV RNA levels,
it may slow the increase of viral levels. It is also possible that
praziquantel treatment may enhance immunocompetence by
promoting an increase in CD4+ T-cell counts and an increased
NK cell function [69–71].
Conclusions
Schistosoma haematobium infection is highly prevalent in sub-
Saharan Africa. Increasing evidence supports that it is a plausible
risk factor for HIV acquisition due both to its local genital tract
effects in women, and to its chronic immunomodulatory effects in
both men and women. It also could facilitate HIV transmission to
the sexual partners of HIV-positive individuals with schistosomal
co-infection, and could enhance HIV disease progression.
Circumstantial, biological, immunological, and epidemiological
evidence is strongly suggestive of a cause-effect relationship
between S. haematobium and HIV infection.
Our review highlights the need for further innovative research,
particularly appropriately-designed longitudinal studies which ulti-
mately would be able to confirm the suggested causality of
schistosomiasis in incident HIV infections. Such studies must
carefully balance the ethical obligation to ensure treatment for study
subjects while simultaneously managing to explore the cause-effect
relationship between the two infections. This is by no means an easy
task. Consideration should therefore be given to harnessing latent
operational research opportunities that exist within the context of
ongoingschistosomiasiscontrolprograms.Theseincludestudiessuch
as exploring the effect of early, regular anti-schistosomal treatment of
girls to prevent development of urogenital lesions in adolescence or
testing for markers of active schistosomiasis in blood collected from
HIV-positive women before their HIV-seroconversion.
Meanwhile, in schistosomiasis-endemic areas where coverage for
preventive chemotherapywith praziquantel remainslow,millionsof
individuals may be at higher risk for HIV infection. The
presumptive causal association with HIV infection notwithstanding,
urogenital schistosomiasis by itself leads to significant morbidity that
can be lessened with inexpensive preventive chemotherapy. At an
annual cost of about 40 cents per person [72–73], praziquantel
stands as a powerful and economical public health intervention with
the potential to prevent the development of urogenital lesions,
prolong survival, and decrease new HIV infections on the African
continent. In view of the plausible association between urogenital
schistosomiasis and HIV transmission in areas where these
infections are co-endemic, a salient effect on the health of millions
of individuals could presumably be achieved if antischistosomal
treatment and HIV prevention interventions were integrated. The
WHO-recommended policy of early regular treatment of school-
age children with praziquantel needs to be extended to adults and
prioritized in national programs as a possible means of further
preventing HIV infections in sub-Saharan Africa.
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